Analysis Tools
adipose tissue
|
• tamoxifen-treated mice show a reduction in subcutaneous adipose tissue at P90, but not at P45
|
|
• tamoxifen-treated mice show a reduction in visceral adipose tissue at P90, but not at P45
|
behavior/neurological
|
• individual orientation behaviors are lower at P42, P49, P56, and P63, except for orient-shuffle at P42 which shows a trend towards lower performance, indicating that mice spend less time assessing risk at all time points
• however, tamoxifen-treated mice show no differences in anxiety-like behavior
|
|
• tamoxifen-treated mice spend less time grooming their legs and back starting at P49 and progressing to P63 and head grooming is reduced at P63
|
|
• tamoxifen-treated mice spend less time rearing at most time points, indicating lower levels of exploration
|
|
• overall locomotor activity is decreased in tamoxifen-treated mice, with reduced track length at P42, P49, P56, and P63 and mice spend less time running and more time standing still at all time points
|
digestive/alimentary system
|
• tamoxifen-treated mice exhibit pronounced and severe exocrine pancreatic atrophy at P42 and P90, respectively
|
endocrine/exocrine glands
|
• tamoxifen-treated mice exhibit pronounced and severe exocrine pancreatic atrophy at P42 and P90, respectively
|
growth/size/body
|
• mice administered five tamoxifen injections every other day starting at P28 exhibit lower body weight, with weight differences appearing at P34 and becoming progressively larger as mice lose weight over time while controls gain weight over time
|
hematopoietic system
|
• tamoxifen-treated mice show reactive microglia in cerebra, as evidenced by the increased cell density and enlarged cell bodies and shorter, thicker processes of Iba1-stained cells in the cortex and particularly in the striatum
|
homeostasis/metabolism
| N |
• tamoxifen-treated mice show normal blood glucose concentrations upon feeding and in either the fasted or the refed state and normal glucose tolerance
|
immune system
|
• tamoxifen-treated mice show reactive microglia in cerebra, as evidenced by the increased cell density and enlarged cell bodies and shorter, thicker processes of Iba1-stained cells in the cortex and particularly in the striatum
|
integument
|
• tamoxifen-treated mice show a reduction in subcutaneous adipose tissue at P90, but not at P45
|
nervous system
|
• gene-expression analysis indicates a reduction in oligodendrocytes in tamoxifen-treated mice
|
|
• tamoxifen-treated mice show reactive microglia in cerebra, as evidenced by the increased cell density and enlarged cell bodies and shorter, thicker processes of Iba1-stained cells in the cortex and particularly in the striatum
|
|
• gene-expression analysis of tamoxifen-treated mice indicates a reduction in neurons in cerebra at P75 and the cerebral cortex shows a reduced number of NeuN+ neurons, indicating cerebral neurodegeneration
|
|
• tamoxifen-treated mice show impaired myelin deposition in the hippocampus, and thalamus (cerebrum) in adolescent (P42) and adult (P90) mice and in the cortex at P90
• however, no differences in myelin in the cerebellum, granular cell layer neurons or Purkinje cell density are seen
|
cellular
|
• gene-expression analysis indicates a reduction in oligodendrocytes in tamoxifen-treated mice
|
|
• tamoxifen-treated mice show reactive microglia in cerebra, as evidenced by the increased cell density and enlarged cell bodies and shorter, thicker processes of Iba1-stained cells in the cortex and particularly in the striatum
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| hypomyelinating leukodystrophy 7 | DOID:0060794 |
OMIM:607694 |
J:364909 | |
